Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity (2013 - 2026)

Amphastar Pharmaceuticals' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1.35% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 5.1% YoY), while the FY2025 annual figure was $1.6 billion, up 3.29% from the prior year.
• Liabilities and Shareholders Equity was $1.6 billion for Q1 2026 at Amphastar Pharmaceuticals, up from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.7 billion in Q3 2025 to a low of $716.2 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity soared 112.56% in 2023, then gained 0.04% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $742.0 million in 2022, then jumped by 103.9% to $1.5 billion in 2023, then increased by 4.27% to $1.6 billion in 2024, then advanced by 3.29% to $1.6 billion in 2025, then climbed by 1.16% to $1.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.